The trial will evaluate the impact of a bacteriophage mixture on Pseudomonas aeruginosa in volunteers with CF

Tuesday, October 4, 2022 NIH-Supported Clinical Trial of Phage Therapy for Cystic Fibrosis Begins Bacteriophages, or "phages," are viruses which naturally attack specific kinds of bacteria. Researchers have long recognized that they could hold potential as a therapeutic for treating bacterial infections, especially those with resistance to antibiotics. However, there are still many gaps in researchers' knowledge about these useful viruses. A new clinical trial, conducted by the NIAID-supported Antibacterial Resistance Leadership Group, will evaluate the impact of a bacteriophage mixture in volunteers with cystic fibrosis (CF) who carry Pseudomonas aeruginosa bacteria in their lungs. P. aeruginosa is a common cause of lung infections in people with cystic fibrosis, and is becoming difficult to treat due to antibiotic resistance. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107